Molecular therapies in thyroid cancer

Timothy Huyck, Mark Agulnik*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Thyroid cancer is a common diagnosis with greater than 34,000 cases per year in the United States. Early stage thyroid cancer is often managed with surgical intervention and radioactive iodine; however, for recurrent or metastatic disease, the treatment options, historically, have been limited to chemotherapy. Chemotherapy for metastatic thyroid cancer has been of limited efficacy. Encouragingly, molecular therapeutics have played a greater role in managing patients with advanced disease. These agents work primarily through disruption of tyrosine kinase pathways. This review will discuss the expanding role of molecular targets in managing patients with advanced thyroid cancer.

Original languageEnglish (US)
Pages (from-to)91-100
Number of pages10
JournalPharmaceuticals
Volume4
Issue number1
DOIs
StatePublished - 2011

Keywords

  • Advanced thyroid cancer
  • Molecular therapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Molecular therapies in thyroid cancer'. Together they form a unique fingerprint.

Cite this